NYSE · LLY
Eli Lilly and Company
$1,427.01+$53.31 (+3.88%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · CAI · USD
Stock price, earnings
Quote as of Oct 30, 2026, 02:16 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Caris Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Caris Life Sciences, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Caris Life Sciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Jun 9, 2025 | -$0.35-60.32% vs estimate | $120.91M-12.41% vs estimate |
|---|
| Q3 2021 | Nov 5, 2021 | $2.95+383.61% vs estimate | $100.83M+11.73% vs estimate |
|---|
| Q2 2021 | Aug 3, 2021 | $2.20+83.33% vs estimate | $85.70M-5.03% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $27.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,427.01+$53.31 (+3.88%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$277.77+$2.57 (+0.93%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 1.17% below the high.
$27.30-$0.87 (-3.08%)
Adaptive Biotechnologies Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.18% below the high.
$17.73-$0.20 (-1.12%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.01% below the high.
$68.37-$2.65 (-3.73%)
GeneDx Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 59.99% below the high.
$15.84-$0.09 (-0.57%)
Personalis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
$37.78-$0.73 (-1.9%)
Castle Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.68% below the high.
$3.01-$0.17 (-5.35%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.63% below the high.
